Christopher Lubker

Soborg, Denmark

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Semaglutide and Hospitalizations in Patients With Obesity and Established Cardiovascular Disease: An Exploratory Analysis of the SELECT Randomized Clinical Trial.

Semaglutide and Hospitalizations in Patients With Obesity and Established Cardiovascular Disease: An Exploratory Analysis of the SELECT Randomized Clinical Trial.

Journal: JAMA cardiology

Published: December 23, 2025

External Validation of SELECT Trial-Derived Cardiovascular Risk Equations in a UK Population with Overweight or Obesity and Established Cardiovascular Disease Without Diabetes.

External Validation of SELECT Trial-Derived Cardiovascular Risk Equations in a UK Population with Overweight or Obesity and Established Cardiovascular Disease Without Diabetes.

Journal: PharmacoEconomics

Published: December 12, 2025

The evolving burden of obesity in the US: a novel population-level system dynamics approach.

The evolving burden of obesity in the US: a novel population-level system dynamics approach.

Journal: Journal of medical economics

Published: August 29, 2025

Inequality in obesity complications, multimorbidity and healthcare costs by deprivation group among people living with obesity: a UK observational study.

Inequality in obesity complications, multimorbidity and healthcare costs by deprivation group among people living with obesity: a UK observational study.

Journal: Journal of epidemiology and community health

Published: August 18, 2025

External Validation of the MicroSimulation Core Obesity Model (MS-COM) to Predict Cardiovascular Outcomes, Mortality and Type 2 Diabetes Mellitus Incidence and Assess Cost Effectiveness.

External Validation of the MicroSimulation Core Obesity Model (MS-COM) to Predict Cardiovascular Outcomes, Mortality and Type 2 Diabetes Mellitus Incidence and Assess Cost Effectiveness.

Journal: PharmacoEconomics

Published: July 06, 2025

Development of Cardiovascular Risk Equations in People with Overweight or Obesity and Established Cardiovascular Disease Without Diabetes Based on the SELECT Trial.

Development of Cardiovascular Risk Equations in People with Overweight or Obesity and Established Cardiovascular Disease Without Diabetes Based on the SELECT Trial.

Journal: PharmacoEconomics

Published: June 06, 2025

Impact of Body Mass Index and Comorbidities on Health-Related Quality of Life and Work Productivity in People With Overweight or Obesity: A Survey-Based Study in the United Kingdom.

Impact of Body Mass Index and Comorbidities on Health-Related Quality of Life and Work Productivity in People With Overweight or Obesity: A Survey-Based Study in the United Kingdom.

Journal: Journal of health economics and outcomes research

Published: June 04, 2025

Cost-effectiveness of semaglutide in people with obesity and cardiovascular disease without diabetes.

Cost-effectiveness of semaglutide in people with obesity and cardiovascular disease without diabetes.

Journal: Journal of medical economics

Published: January 30, 2025

The Composite Number Needed to Treat for Semaglutide in Populations with Overweight or Obesity and Established Cardiovascular Disease Without Diabetes.

The Composite Number Needed to Treat for Semaglutide in Populations with Overweight or Obesity and Established Cardiovascular Disease Without Diabetes.

Journal: Advances in therapy

Published: January 13, 2025

Educational inequalities in deaths of despair in 14 OECD countries: a cross-sectional observational study.

Educational inequalities in deaths of despair in 14 OECD countries: a cross-sectional observational study.

Journal: Journal of epidemiology and community health

Published: February 21, 2024

The association between body mass index and health-related quality of life in the 2017 and 2018 health survey of England data: A cross-sectional observational analysis.

The association between body mass index and health-related quality of life in the 2017 and 2018 health survey of England data: A cross-sectional observational analysis.

Journal: Diabetes, obesity & metabolism

Published: December 06, 2023

The improved health utility of once-weekly subcutaneous semaglutide 2.4 mg compared with placebo in the STEP 1-4 obesity trials.

The improved health utility of once-weekly subcutaneous semaglutide 2.4 mg compared with placebo in the STEP 1-4 obesity trials.

Journal: Diabetes, obesity & metabolism

Published: December 21, 2022

Showing 1-12 of 14

Last Updated: 09/26/2026